Cancer Conference Update: A Multimedia Review of Key Presentations from the 2016 American Society of Hematology Annual MeetingAbstract 343: Enasidenib (AG-221), a potent oral inhibitor of mutant IDH2 enzyme, induces hematologic responses in MDS
1:38 minutes.
TRANSCRIPTION:
DR LOVE: So how about abstract 343 looking at AG-221, enasidenib? What is it, and what do we know about it in MDS? DR STEENSMA: It’s always encouraging when a drug gets a name, because it’s moving farther along. And that’s what we see here with AG-221. And so Eytan Stein, who’s a wonderful young oncologist at Memorial Sloan Kettering Cancer Center, presented some data from 16 patients with high-risk MDS who had IDH mutations. Now, IDH mutations are not as common in MDS as they are in AML. We’re talking 5% to 10% overall in MDS. But they are out there. And this agent did induce responses in those with the IDH2 mutation. The CR rate was low, but the overall response rate was 53%, 8 out of 15 evaluable patients. Some of them, including one of my own patients, were then able to go on and have successful allogeneic transplant. And that, I think, may be the role for IDH inhibition in MDS, if the patient has a transplant option. You could use a hypomethylating agent to bridge them to transplant. If they have an IDH mutation, maybe you use this agent instead and a hypomethylating agent only if it doesn’t work. Potentially in the future, if we get more data on the combination, we could use them together. |